Prometheus Biosciences, Inc. RXDX
At closeJun 15, 2023, 4:00 PM EDT
52-week range unavailable
- Market cap
- 9.56B
- Revenue (ttm)
- 4.00M
- Shares out
- 47.81M
- Forward P/E
- -44.33
- Volume
- 1.79M
- Open
- 199.68
- Previous close
- 199.92
- Day's range
- 199.92 – 199.96
- Beta
- -0.49
- Analysts
- Buy
- Price target
- 190.00 (-5.0%)
- Earnings date
- Aug 10, 2023
2Y +164.46 (+463.79%)
Key statistics
- Enterprise value
- 8.87B
- PEG ratio
- 0.00
- Price / sales
- 2392.62
- Price / book
- 13.67
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -71.80%
- Free cash flow
- -81.39M
- Total cash
- 713.67M
- Total debt
- 29.46M
- Return on equity
- -33.30%
- Short % of float
- 9.79%
- 50-day average
- 189.46
- 200-day average
- 112.93
Analyst view
Consensus: buy
- Target (low)
- 160.00
- Target (mean)
- 190.00
- Target (high)
- 200.00
- Strong buy2
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 10, 2023
Expected Aug 10, 2023. Consensus EPS estimate -0.94.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 10, 2023 | Jun 1, 2023 | -0.91 | — | — | — |
| May 9, 2023 | Mar 1, 2023 | -0.92 | — | — | — |
| Feb 28, 2023 | Dec 1, 2022 | -0.91 | — | — | — |
| Nov 9, 2022 | Sep 1, 2022 | -0.89 | — | — | — |
| Aug 11, 2022 | Jun 1, 2022 | -0.92 | — | — | — |
| May 12, 2022 | Mar 1, 2022 | -0.78 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 10, 2023 | RBC Capital | main | — | Sector Perform |
| May 10, 2023 | Jefferies | down | Buy | Hold |
| Apr 18, 2023 | Wells Fargo | down | Overweight | Equal-Weight |
| Apr 18, 2023 | Credit Suisse | down | Outperform | Neutral |
| Apr 18, 2023 | RBC Capital | down | Outperform | Sector Perform |
| Apr 18, 2023 | Piper Sandler | down | Overweight | Neutral |
About Prometheus Biosciences, Inc.
Prometheus Biosciences, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR300, a G-protein coupled receptor modulator for IBD and potentially other immune-mediated diseases; PRA052, an anti-CD30L mAb for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; and PR2100, an anti-inflammatory cytokine mAb for IBD, and inflammatory and fibrotic diseases. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH for PRA052; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California. As of June 16, 2023, Prometheus Biosciences, Inc. operates as a subsidiary of Merck & Co., Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- prometheusbiosciences.com
News
Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2023 
Here Are The Best-Performing Industry ETFs And Major Stock Contributors In April 
Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2023 
Gold Drops Below $2,000; Charles Schwab Earnings Top Views 
52 Biggest Movers From Friday 
44 Biggest Movers From Yesterday 
58 Biggest Movers From Yesterday - 50 Biggest Movers From Yesterday
- 42 Stocks Moving In Monday's Mid-Day Session
- 44 Biggest Movers From Yesterday
Your note
Sign in to keep a note on RXDX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADAMS HELEN C | Director | Stock Award(Grant) | May 18, 2023 | 2,674 |
| CEDARS SINAI INTELLECTUAL PROPERTY CO | Beneficial Owner of more than 10% of a Class of Security | Sale | Mar 7, 2023 | 0 |
| HASSAN FRED | Director | Stock Award(Grant) | May 18, 2023 | 2,123 |
| HENDRIX MARTIN | Director | Stock Award(Grant) | May 18, 2023 | 2,071 |
| LAUR JAMES | Director | Stock Award(Grant) | May 18, 2023 | 2,071 |
| MARSHALL KEITH W. | Chief Financial Officer | Conversion of Exercise of derivative security | Jun 1, 2023 | 87,973 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RTW Investments LP | 6.84% | 3,272,104 | 654.16M | Mar 30, 2023 |
| Blackrock Inc. | 5.86% | 2,799,818 | 559.74M | Mar 30, 2023 |
| Vanguard Group, Inc. (The) | 5.68% | 2,716,901 | 543.16M | Mar 30, 2023 |
| Boxer Capital, LLC | 3.97% | 1,897,500 | 379.35M | Mar 30, 2023 |
| 72 Investment Holdings, LLC | 3.87% | 1,848,024 | 369.46M | Mar 30, 2023 |
| Cormorant Asset Management, LP | 3.46% | 1,655,000 | 330.87M | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.23% | 1,060,681 | 212.05M | Dec 30, 2022 |
| Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund | 1.75% | 832,938 | 166.52M | Dec 30, 2022 |
| iShares Russell 2000 ETF | 1.61% | 765,275 | 152.99M | Feb 27, 2023 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 1.32% | 625,964 | 125.14M | Feb 27, 2023 |
| Vanguard Extended Market Index Fund | 0.98% | 465,623 | 93.09M | Dec 30, 2022 |
| Fidelity Select Portfolios - Biotechnology | 0.84% | 397,555 | 79.48M | Feb 27, 2023 |